Post-earnings recap
Reported
Tue, Nov 12, 2024
EPS actual
$-1.34
EPS est.
$-1.38
EPS surprise
+3.18%
1-day move
+9.35%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Axovant Therapeutics reported a narrower-than-expected loss per share, which contributed to a positive stock reaction, with shares rising 9.35%. The company did not disclose revenue figures or future guidance, leaving investors to focus on the EPS beat as a sign of potential improvement. The upbeat tone from management suggests they are optimistic about their ongoing projects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.34 | N/A | +3.18% |
| Revenue | N/A | N/A | N/A |
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. However, they did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.